SuperworthCosmos Health profit margin COSM
Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.
- Net margin, 12 months
- −33.1%
- Operating margin, 12 months
- −24.9%
- Net margin on a year earlier
- −5.2 pts
- Peer median
- 6.8%
Over the twelve months to Jun 30, 2026, Cosmos Health kept −33.1% of its revenue as net profit, with an operating margin of −24.9% and a gross margin of 10.3%.
Five years earlier its net margin was −8.1%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −29.3% | −25.6% | 12.1% |
| FY2024 | −29.7% | −28.6% | 7.9% |
| FY2023 | −34.7% | −40.9% | 8.1% |
| FY2022 | −27.5% | −14.8% | 11.8% |
| FY2021 | −14.2% | −8.1% | 14.8% |
| FY2020 | 1.5% | 4.9% | 14.5% |
| FY2019 | −8.3% | −0.6% | 9.2% |
| FY2018 | −24.4% | −3.3% | 6.5% |
| FY2017 | −20.7% | −16.2% | 6.5% |
| FY2016 | −8.9% | −3.0% | 8.9% |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −33.1% | −5.2 pts | −24.9% | |
| Q1 FY26 | −30.4% | −2.2 pts | −26.0% | |
| Q4 FY25 | −29.3% | +0.4 pts | −25.6% | |
| Q3 FY25 | −20.6% | +26.8 pts | −23.9% | |
| Q2 FY25 | −27.9% | +10.3 pts | −26.7% | |
| Q1 FY25 | −28.3% | +7.6 pts | −27.2% | |
| Q4 FY24 | −29.7% | +5.0 pts | −28.6% | |
| Q3 FY24 | −47.4% | −16.0 pts | −36.0% | |
| Q2 FY24 | −38.2% | −9.0 pts | −37.1% | |
| Q1 FY24 | −35.9% | −6.7 pts | −37.8% | |
| Q4 FY23 | −34.7% | −7.3 pts | −40.9% | |
| Q3 FY23 | −31.5% | −23.3 pts | −31.3% |
Against its peers
Companies in Healthcare nearest Cosmos Health's size, closest first, today.
| Company | Profit margin |
|---|---|
| COSMCosmos Health | −33.1% |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Cosmos Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.